Development and validation of an immune-based nomogram model for predicting severe adenovirus pneumonia in hospitalized children

开发和验证基于免疫的列线图模型,用于预测住院儿童的重症腺病毒肺炎

阅读:1

Abstract

BACKGROUND: Human adenovirus (HAdV) is a significant cause of severe pneumonia in children that often causes sequelae. Although immune disorders are known to be associated with disease progression, comprehensive immunological predictors have not been identified. The purpose of this study was to explore the ability of multiple immunological indicators to predict severe adenovirus pneumonia (SAP) and to develop an immune-based nomogram for the early prediction of SAP in children. METHODS: This study involved a retrospective analysis of children with adenovirus pneumonia who were hospitalized and received treatment at the Department of Respiratory Medicine, Capital Center for Children's Health, Capital Medical University between January 2017 and June 2025. Patients were stratified into mild and severe groups on the basis of clinical manifestations. They were subsequently randomly allocated at an 80:20 ratio into a training set and a cross-validation set for nomogram development and validation. R software (version 4.4.3) was used for statistical analysis, and effect sizes are expressed as odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: Among the 1220 cases included, 357 (29.3%) were classified as severe. In both the training and cross-validation sets, patients with SAP were younger and had longer hospital stays (all P < 0.001). After the adjustments for age and sex, logistic regression in the training set revealed seven significant factors associated with SAP occurrence in children: Mycoplasma pneumoniae infection (OR = 1.372, 95% CI: 1.04-1.809, P < 0.001); complement component 3 (C3) (OR = 0.234, 95% CI: 0.132-0.417, P < 0.001) and 4 (C4) (OR = 0.075, 95% CI: 0.018-0.31, P < 0.001); immunoglobulin G (IgG) (OR = 1.049, 95% CI: 1.028-1.071, P < 0.001); and the percentages of CD3(+) [CD3(+) (%)] (OR = 0.965, 95% CI: 0.952-0.979, P < 0.001), CD4(+) [CD4(+) (%)] (OR = 0.950, 95% CI: 0.934-0.967, P < 0.001), and CD19(+) cells [CD19(+) (%)] (OR = 1.042, 95% CI: 1.028-1.057, P < 0.001). Furthermore, logistic regression of the validation set revealed C3, C4, IgG, CD3(+)(%), CD4(+) (%) and CD19(+)(%) as consistent predictors of SAP across datasets. Incorporating the significant factors improved model discrimination, increasing the area under the curve (AUC) from 0.627 to 0.836 in the training set and from 0.678 to 0.913 in the cross-validation set. The final nomogram model based on the significant factors demonstrated strong calibration and discrimination (C-index: 0.731 in the training set, 0.812 in the cross-validation set), supporting its potential for clinical risk stratification. CONCLUSION: This study identified and validated seven independent factors significantly associated with SAP in children. A nomogram incorporating these factors was developed and it demonstrated favourable discriminative performance and good calibration. The model exhibited high sensitivity and maintained high predictive accuracy across both datasets, indicating its potential clinical utility for individualized risk stratification.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。